ArticleJournal of family medicine and primary care2025
Glycosylated fibronectin as a biomarker to predict gestational diabetes mellitus in the first trimester of pregnancy.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) increases the maternal and fetal risk, including macrosomia, shoulder dystocia or other birth injuries, premature delivery, and preeclampsia. Diagnosis of GDM in early pregnancy may help to prevent these complications. Our study aims to evaluate the usefulness of glycosylated fibronectin in the prediction of GDM in the first trimester of pregnancy and to compare its level in pregnant women with GDM and without GDM. Methods: After ethics approval and written informed consent, this prospective, single-centre, cohort study was done on 120 pregnant women. The sample for the analysis of serum glycosylated fibronectin was collected at 7-13 weeks of gestation and stored at -180 degrees for further analysis by the Western blot method. We used screening strategies as recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) for the detection of GDM by an oral glucose tolerance test (OGTT) after taking 75 grams of glucose at 24-28 weeks of gestation. Out of a total of 120 screened patients, 42 pregnant women by OGTT were diagnosed to have GDM grouped, as cases. A similar number of non-GDM pregnant patients were taken and considered as the control group. Both groups were analyzed for glycosylated fibronectin after getting the result of OGTT between 24-28 weeks of pregnancy. Results: There were decreased levels of first-trimester maternal serum glycosylated fibronectin in GDM than in non-GDM pregnant women with the area under the receiver operating characteristic (ROC) curve was 72.4% (95% CI: 61.6% to 83.2%. Conclusion: We found decreased levels of first-trimester maternal serum glycosylated fibronectin in GDM than in non-GDM pregnant women. This study proves that the glycosylated fibronectin test is of modest diagnostic accuracy and clinical applicability as an early screening method for the prediction of GDM in the first trimester of pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.